NovoCure Limited Ordinary Shares (NVCR) — Analysis Summary
NovoCure Limited Ordinary Shares (NVCR) has a market cap of $2.09B with year-over-year revenue growth of +8.3%. Net margin stands at -20.8%. The stock trades at a P/E ratio of -14.1.
Key Takeaways
- Revenue changed +8.3% year-over-year
- Net margin of -20.8%
- P/E ratio of -14.1
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, NVCR posted revenue growth of +8.3% and trades at a P/E of -14.1.
NovoCure Limited Ordinary Shares (NVCR)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -22.1% — material operating losses
Net margin at -21.2% — significant losses
The latest filing shows negative free cash flow.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
1,605
Headquarters
ST. HELIER
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.